argenx SE (ARGX) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Argenx Se.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.755 with the presentation for today's webcast. 00:00:02.755 -- 00:00:06.781 Before we begin on slide two, I'd like to remind you that forward-looking statements 00:00:06.781 -- 00:00:11.628 may be presented during this call. These may include statements about our future expectations, 00:00:11.628 -- 00:00:16.134 clinical developments, regulatory timelines, the potential success of our product candidates, 00:00:16.134 -- 00:00:19.018 financial projections, and upcoming milestones. 00:00:19.018 -- 00:00:22.745 Actual results may differ materially from those indicated by these statements. 00:00:22.745 -- 00:00:27.070 Our GenX is not under any obligation to update statements regarding the future or to 00:00:27.070 -- 00:00:32.616 conform those statements in relation to actual results unless required by law. 00:00:32.616 -- 00:00:37.441 I'm joined on the call today by Tim Van Haramiren, Chief Executive Officer, Carl Gubitz, 00:00:37.441 -- 00:00:41.466 Chief Financial Officer, and Karen Massey, Chief Operating Officer. 00:00:41.466 -- 00:00:45.230 Luke Trojan, our Chief Medical Officer, will be available during Q&A. 00:00:45.230 -- 00:00:47.833 I'll now turn the call to Tim. 00:00:47.833 -- 00:00:50.276 Thank you, Beth, and welcome, everyone. 00:00:50.276 -- 00:00:55.440 I'll begin on slide number three. At the start of the year, we set a bold growth 00:00:55.440 -- 00:01:00.284 agenda anchored in our long-term roadmap for value creation, Vision 2030. 00:01:00.284 -- 00:01:02.284 Today, 00:01:02.286 -- 00:01:03.707 FlipGuard 00:01:03.707 -- 00:01:09.773 is delivering meaningful impact in two blockbuster indications with MG and CIDP. 00:01:09.773 -- 00:01:14.898 Our pre-filled syringe is now approved in most major markets, fueling new patien...